Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation (“Orion Pharma”) and Qilu Pharma Europe

Follow